Skip to main content
SHANGHAI SERUM BIO-TECHNOLOGY CO., LTD. logo

SHANGHAI SERUM BIO-TECHNOLOGY CO., LTD. — Investor Relations & Filings

Ticker · 688163 ISIN · CNE1000059X8 LEI · 8368001TREMN2G5DDS70 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 335 across all filing types
Latest filing 2024-03-01 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688163

About SHANGHAI SERUM BIO-TECHNOLOGY CO., LTD.

https://www.serum-china.com.cn/en/

Shanghai Serum Bio-Technology Co., Ltd. is a specialized biopharmaceutical enterprise focused on the research, development, and manufacturing of therapeutic biological products. The company primarily produces a range of antiserums and antitoxins, including specialized antivenoms for various snake species, tetanus antitoxins, and rabies immunoglobulins. Its product portfolio supports emergency medical care and infectious disease management. The organization maintains advanced production facilities compliant with Good Manufacturing Practice (GMP) standards to ensure the safety and efficacy of its biological treatments. By leveraging biotechnological innovation, the company serves clinical needs in healthcare sectors, providing critical life-saving interventions for envenomation and acute bacterial toxins.

Recent filings

Filing Released Lang Actions
方正证券承销保荐有限责任公司关于上海赛伦生物技术股份有限公司首次公开发行战略配售限售股上市流通的核查意见
Regulatory Filings Classification · 95% confidence The document is a verification opinion from the underwriting and sponsorship company regarding the listing and circulation of restricted shares from the company's initial public offering (IPO) on the STAR Market. It references regulatory approvals, share issuance details, lock-up periods, and compliance with relevant securities regulations. The document is not a full financial report, earnings release, or management discussion, but rather a formal verification and compliance statement related to the IPO share circulation. It is a specialized regulatory filing related to share issuance and compliance but does not fit the categories of capital/financing update or share issue announcements directly, as it focuses on the verification opinion of restricted shares becoming tradable. Given the nature and content, it best fits under Regulatory Filings (RNS) as a compliance and verification document that does not neatly fit other categories.
2024-03-01 Chinese
赛伦生物：关于副总经理离职暨核心技术人员调整的公告
Board/Management Information Classification · 95% confidence The document is an official announcement from Shanghai SAILUN Biotechnology Co., Ltd. regarding the resignation of a vice general manager and adjustments to core technical personnel. It details the resignation, the appointment of a new core technical person, and the impact on the company. There are no financial statements, no quarterly or annual report data, no earnings information, no voting results, no merger or acquisition details, and no regulatory certifications. The content focuses on management changes specifically related to senior management and core technical personnel. Therefore, this fits the category of Board/Management Information (MANG). The document length is 3594 characters, which is consistent with a detailed announcement but not a full report. Confidence is high due to clear content about management changes and no other competing categories.
2024-03-01 Chinese
方正证券承销保荐有限责任公司关于上海赛伦生物技术股份有限公司副总经理离职暨核心技术人员调整的核查意见
Board/Management Information Classification · 95% confidence The document is a detailed verification opinion from the sponsor institution (方正证券承销保荐有限责任公司) regarding the resignation of the deputy general manager and adjustment of core technical personnel at Shanghai Sailun Biotechnology Co., Ltd. It includes biographical details, shareholdings, patent involvement, confidentiality and non-compete agreements, and the impact assessment of the personnel changes on the company. The document is regulatory in nature, related to personnel changes at senior management and core technical staff, but it is not a full annual or interim report, nor an earnings release or call transcript. It is not a simple announcement but a formal verification opinion by the sponsor. This fits best under Board/Management Information (MANG) as it concerns changes in senior management and key personnel with detailed background and impact analysis.
2024-03-01 Chinese
赛伦生物：2023年度业绩快报公告
Earnings Release Classification · 95% confidence The document is titled as a "2023年度业绩快报公告" which translates to "2023 Annual Performance Express Announcement". It contains preliminary financial data for the full year 2023, including revenue, profit, net income, and other key financial metrics. The data is explicitly stated as preliminary and unaudited, with a note that the final audited figures will be disclosed in the company's full 2023 Annual Report. The document is relatively short (1955 characters) and serves as an initial announcement of the annual financial results rather than a comprehensive annual report. This matches the characteristics of an Earnings Release (ER), which is an initial announcement of quarterly or annual financial results with key highlights only. It is not a full Annual Report (10-K) or Interim Report (IR) because it lacks detailed financial statements and analysis, and it is not an announcement of report publication (RPA) because it contains substantive preliminary financial data. Therefore, the correct classification is Earnings Release (ER). FY 2023
2024-02-23 Chinese
赛伦生物：关于实际控制人之一、董事、总经理及部分高级管理人员增持股份计划的公告
Director's Dealing Classification · 95% confidence The document is an announcement regarding a shareholding increase plan by key company insiders including the actual controller, directors, and senior management. It details the planned purchase amounts, timing, and methods for acquiring additional shares. The content focuses on insider share transactions and plans to increase holdings, rather than financial results, governance changes, or regulatory filings. The document length is 2238 characters, which is relatively short but contains substantive information about insider share transactions. Therefore, it fits the category of Director's Dealing (DIRS), which covers reports of personal share transactions by company directors and executives.
2024-02-23 Chinese
方正证券承销保荐有限责任公司关于上海赛伦生物技术股份有限公司2023年度持续督导工作现场检查报告
Audit Report / Information Classification · 95% confidence The document is titled as a "2023年度持续督导工作现场检查报告" which translates to "2023 Annual Continuous Supervision On-site Inspection Report" by the underwriting and sponsoring institution for Shanghai Sailun Biotechnology Co., Ltd. It details the on-site inspection of the company's governance, internal controls, information disclosure, independence, use of raised funds, related party transactions, guarantees, major investments, and business operations during the 2023 continuous supervision period. The document is a detailed report of the sponsor's supervisory activities and findings rather than a general annual report or audit report. It is not an announcement or a brief notice but a substantive report on the continuous supervision work. This type of document is a specialized audit or supervisory report related to regulatory compliance and ongoing sponsor oversight, fitting best under the category of Audit Report / Information (AR). The document length is 2777 characters, which is substantive but not extremely long, consistent with a focused audit/supervisory report rather than a full annual report (10-K) or interim report (IR). There is no indication that this is a mere announcement or certification, so it is not RPA or RNS. Therefore, the best classification is AR with high confidence. FY 2023
2024-01-19 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.